| Pharmaceutical Information |
| Drug Name |
Nelarabine |
| Drug ID |
BADD_D01549 |
| Description |
Nelarabine is an antineoplastic agent that is typically employed to treat acute T-cell lymphoblastic leukemia. Nelarabine is a purine nucleoside analog converted to its corresponding arabinosylguanine nucleotide triphosphate (araGTP), resulting in inhibition of DNA synthesis and cytotoxicity. |
| Indications and Usage |
For the treatment of pediatric and adult patients with acute T-cell lymphoblastic leukemia and T-cell lymphoblastic lymphoma whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01BB07 |
| DrugBank ID |
DB01280
|
| KEGG ID |
D05134
|
| MeSH ID |
C104457
|
| PubChem ID |
3011155
|
| TTD Drug ID |
D0B8UJ
|
| NDC Product Code |
54893-0118; 70710-1726; 77391-004; 61187-006; 76055-0048; 0078-0683; 43598-142; 70121-1743; 70710-1839; 70771-1685; 71288-165; 81927-111 |
| UNII |
60158CV180
|
| Synonyms |
nelarabine | 2-amino-9-beta-D-arabinofuranosyl-6-methoxy-9H-purine | 2-amino-6-methoxypurine arabinoside | Arranon | GW506U78 | 506U78 | compound 506U78 |
|
| Chemical Information |
| Molecular Formula |
C11H15N5O5 |
| CAS Registry Number |
121032-29-9 |
| SMILES |
COC1=NC(=NC2=C1N=CN2C3C(C(C(O3)CO)O)O)N |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
